Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset
Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to expand its rights to the asset in exc...
Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to expand its rights to the asset in exchange for a further $80 million.